(Q39458047)

12 September 2017

1 reference

title

Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective (English)

1 reference

12 September 2017

Eri LM

1

1 reference

12 September 2017

Tveter KJ

series ordinal

2

1 reference

12 September 2017

publication date

1 February 1997

1 reference

12 September 2017

1 reference

12 September 2017

volume

10

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

107-118

1 reference

Benign prostatic hyperplasia--are we too "hot" on new therapies?

12 September 2017

cites work

1 reference

12 December 2020

The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia.

1 reference

12 December 2020

The changing therapy of benign prostatic hyperplasia.

1 reference

12 December 2020

High prevalence of benign prostatic hypertrophy in the community

1 reference

12 December 2020

Urinary symptoms in the community: how bothersome are they?

1 reference

12 December 2020

The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report

1 reference

12 December 2020

Comparative Study of Selective α1-Adrenoceptor BlockadeversusSurgery in the Treatment of Prostatic Obstruction

1 reference

12 December 2020

Perspectives on the management of benign prostatic hyperplasia

1 reference

12 December 2020

Future directions in the management of benign prostatic hyperplasia

1 reference

12 December 2020

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

12 December 2020

New use for alpha blockers: benign prostatic hyperplasia.

1 reference

12 December 2020

The costs of prostatectomy for benign prostatic hyperplasia.

1 reference

12 December 2020

International comparison of the community prevalence of symptoms of prostatism in four countries.

1 reference

12 December 2020

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

12 December 2020

Cost consequences of surveillance, medical management or surgery for benign prostatic hyperplasia.

1 reference

12 December 2020

Treatment of benign prostatic hyperplasia

1 reference

12 December 2020

A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Some clinical aspects of uroflowmetry in elderly males. A population survey

1 reference

12 December 2020

Natural history of benign prostatic hyperplasia and risk of prostatectomy. The Baltimore Longitudinal Study of Aging

1 reference

12 December 2020

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

1 reference

12 December 2020

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

12 December 2020

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

12 December 2020

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Europe

1 reference

12 December 2020

1 reference

12 December 2020

Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride.

1 reference

12 December 2020

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

12 December 2020

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

12 December 2020

Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.

1 reference

12 December 2020

BPH epidemiology and risk factors

1 reference

12 December 2020

The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension

1 reference

12 December 2020

Controversies about indications for transurethral resection of the prostate.

1 reference

12 December 2020

New words for old: lower urinary tract symptoms for "prostatism"

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial

1 reference

12 December 2020

The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives

1 reference

12 December 2020

Estimated total costs of treating benign prostatic hyperplasia in Sweden

1 reference

12 December 2020

The effect of finasteride on prostate specific antigen: review of available data

1 reference

12 December 2020

Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men.

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients

1 reference

12 December 2020

Urodynamics in benign prostatic hyperplasia: a survey.

1 reference

12 December 2020

New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States

1 reference

12 December 2020

Proscar: five-year experience.

1 reference

12 December 2020

The effect of finasteride on prostate‐specific antigen in men with benign prostatic hyperplasia

1 reference

12 December 2020

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension

1 reference

12 December 2020

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

12 December 2020

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

The prevalence of prostatism: a population-based survey of urinary symptoms

1 reference

12 December 2020

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Medical management of benign prostatic hyperplasia

1 reference

12 December 2020

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

12 December 2020

Efficacy of once-A-day terazosin in benign prostatic hyperplasia: A randomized, double-blind placebo-controlled clinical trial

1 reference

12 December 2020

Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens

1 reference

12 December 2020

The prostate: an increasing medical problem

1 reference

12 December 2020

Decrease in mortality from benign prostatic hyperplasia: a major unheralded health triumph.

1 reference

12 December 2020

Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States

1 reference

12 December 2020

Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists

1 reference

12 December 2020

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

1 reference

12 December 2020

Urologists on a tightrope: coping with a changing economy.

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Effect of Age, Educational Status, Ethnicity and Geographic Location on Prostate Symptom Scores

1 reference

12 December 2020

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

12 December 2020

The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia

1 reference

12 December 2020

The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study

1 reference

12 December 2020

10.2165/00002512-199710020-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

12 September 2017

1046687354

0 references

Fatcat ID

release_lae3c4ixijab3ebfq24sykmzuu

0 references

1 reference